4D Molecular Therapeutics FDMT Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's other income, net (note 6)?
- 4D Molecular Therapeutics (FDMT) reported other income, net (note 6) of -$4K in Q1 2026.
- How has 4D Molecular Therapeutics's other income, net (note 6) changed year-over-year?
- 4D Molecular Therapeutics's other income, net (note 6) decreased by 106.0% year-over-year, from $67K to -$4K.
- What is the long-term trend for 4D Molecular Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's other income, net (note 6) has grown at a -25.6% compound annual growth rate (CAGR), from -$121K to -$37K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.